Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 369
EU - Europa 222
AS - Asia 45
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 645
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 363
IT - Italia 107
DE - Germania 37
FR - Francia 35
AT - Austria 24
CN - Cina 19
CA - Canada 6
VN - Vietnam 6
AE - Emirati Arabi Uniti 5
IE - Irlanda 5
IN - India 5
CZ - Repubblica Ceca 3
FI - Finlandia 3
GH - Ghana 3
HK - Hong Kong 3
ZA - Sudafrica 3
BE - Belgio 2
CH - Svizzera 2
GB - Regno Unito 2
SG - Singapore 2
CI - Costa d'Avorio 1
EU - Europa 1
ID - Indonesia 1
IR - Iran 1
JP - Giappone 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RU - Federazione Russa 1
TH - Thailandia 1
UA - Ucraina 1
Totale 645
Salva come PNG Salva come JPEG
Città #
Santa Cruz 52
Fairfield 47
Milan 46
Vienna 24
Ashburn 18
Buffalo 18
Woodbridge 18
Frankfurt am Main 17
Seattle 16
Cambridge 15
Houston 15
Ann Arbor 9
Boardman 6
Columbus 6
Las Vegas 6
Shanghai 6
Wilmington 6
Andover 5
Beijing 5
Dong Ket 5
University Park 5
Wuhan 5
Dublin 4
Mountain View 4
Redmond 4
San Diego 4
Chicago 3
Guangzhou 3
New York 3
Riva 3
Toronto 3
Athens 2
Brussels 2
Des Moines 2
Flüelen 2
Helsinki 2
Herndon 2
Lake Forest 2
Legnano 2
Muizenberg 2
Napoli 2
Ottawa 2
Palo Alto 2
Paris 2
Pavia 2
Phoenix 2
Rome 2
Singapore 2
Atlanta 1
Auckland 1
Bari 1
Bengaluru 1
Boiling Springs 1
Bologna 1
Brescia 1
Büdelsdorf 1
Coimbatore 1
Darmstadt 1
Duncan 1
Ercolano 1
Fremont 1
Ghaziabad 1
Indore 1
Lahore 1
Lappeenranta 1
Malang 1
Mumbai 1
North Truro 1
North Vancouver 1
Oak Lawn 1
Perugia 1
Piscataway 1
Provo 1
Salt Lake City 1
Silverton 1
Simi Valley 1
Tehran 1
Tokyo 1
Turin 1
Venice 1
Totale 447
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma, file e39773b5-938d-35a3-e053-3a05fe0aac26 141
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose, file e39773b2-26d7-35a3-e053-3a05fe0aac26 85
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience, file e39773b7-68f9-35a3-e053-3a05fe0aac26 68
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases, file e39773b6-e6dd-35a3-e053-3a05fe0aac26 54
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience, file e39773b7-9535-35a3-e053-3a05fe0aac26 53
Focus on nivolumab in NSCLC, file e39773b7-8fbb-35a3-e053-3a05fe0aac26 52
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial, file e39773b7-9314-35a3-e053-3a05fe0aac26 50
Novel cytotoxic chemotherapies in small cell lung carcinoma, file e39773b7-6dd6-35a3-e053-3a05fe0aac26 47
A new race against lung cancer, file b077a8ac-a243-4e80-8a91-360d9865975d 8
How to describe univariate data, file 5b8215c3-ce55-46fa-a000-c649d78b4c6b 7
Maintenance therapy in NSCLC: why? To whom? Which agent?, file 74091dd2-f1d1-4a11-9511-631d2457008f 7
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials, file 8cb620c4-3d28-4c1b-b4d6-3f754ee2536b 7
Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting, file 37d4373f-37b2-41bc-8085-5cb9f0bdda43 6
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey, file 78a55e38-4e82-4a2f-9317-f2f6d463c2ba 6
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma, file a74232a5-d5ea-402d-b6f3-b71e0f34c496 5
Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice, file fc9d11a5-148d-40fa-86ca-eb4eb7f0b545 5
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians, file fafc95cf-6f0b-4ef9-9a58-aa7f2a65d4b0 4
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group, file 19d40a3e-4a52-4f03-94f8-14a807dcfe60 3
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study, file 4f9de21e-9e39-4a2d-81b8-2f65912b1c6a 3
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study, file 05c73857-8306-460e-a1c0-9d6d99208451 2
Histologically customized and maintenance chemotherapy in advanced non-small cell lung cancer, file 0855468d-42f7-4d67-b654-8e638d2273be 2
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study, file 20a3460e-f02f-4290-acaf-2da4e4784fdc 2
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy, file 365c3981-fbce-488f-b5f1-a305818070f2 2
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, file 50959bce-30e5-4282-99b4-4d9a5286f273 2
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues, file 509b3943-48a0-42ce-97e2-686cf5648f84 2
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study, file 57d5a488-d36e-4798-ad2a-410745190746 2
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study, file 7dbb0b7b-27d4-4e67-a12f-b6b551f367d1 2
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC, file 877b8bf7-5f3a-4016-8567-fc29d7fd4282 2
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study, file a0d593d0-128d-418c-bd99-c7bc1fdea3e7 2
Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey, file ab97714f-0582-435c-ad4a-1d52d5d4b47f 2
Advanced non-small cell lung cancer management in patients progressing after first-line treatment : results of the cross-sectional phase of the Italian LIFE observational study, file b3940581-9e9d-43d8-9f9b-e2eb24f2664a 2
Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey, file b84cd4ff-fa3b-41ab-ae0d-98543fce4e65 2
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA), file c5fdad47-4be3-442f-9bb7-d2b9549ef8ae 2
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study, file ccd8710e-2b63-456e-bbbf-ba35653b7d8d 2
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma, file d1891bee-541f-4897-9cc4-9385e8098d7e 2
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors, file d6a70fa6-91a3-46fb-9a83-9e71f376175f 2
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, file df94af80-ba1d-42dd-8412-566b97656121 2
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study, file e9a13ef6-48ac-47de-9db2-cb51a31ac177 2
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence, file e9ef5ea0-b358-49e2-a90f-6366062695d7 2
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians, file f8308f72-de91-4709-8e54-b91e36e8f684 2
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer, file e39773b5-f1e2-35a3-e053-3a05fe0aac26 1
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer, file e39773b6-2d38-35a3-e053-3a05fe0aac26 1
Totale 655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.232
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196 0 0 0 0 0 0 0 0 0 0 2 4
2019/202062 1 0 14 7 7 5 5 9 6 3 3 2
2020/202189 2 6 2 1 7 5 2 6 8 17 14 19
2021/2022148 8 8 8 11 10 10 4 10 4 8 48 19
2022/2023147 9 21 54 18 7 5 2 1 8 6 12 4
2023/2024156 2 3 2 2 77 23 13 6 16 7 5 0
Totale 655